Market Newsdesk

Bruker Introduces Novel 4D-Proteomics^™timsTOF^® Capabilities

1. New AI-powered TIMSquant^™ software for CCS-enabled, label-free quantification scalable to thousands of samples
2. Early midia-PASEF^® access for immunopeptidomics and PTMs on ultra-sensitive timsTOF Ultra for DDA-like precursor traceability in dia-PASEF
3. Affordable, high-throughput ~3,500 PG plasma proteomics on timsTOF HT with PreOmics ENRICH kit using Biognosys Spectronaut^® 18 directDIA+^™ software
4. New PepSep^™ ULTRA XL and MAX HT nano-LC columns for DDA library creation and high-throughput proteomics, respectively
5. Novel TwinScape^™ digital twin for optimal timsTOF performance and uptime
6. New partnership with Mass Dynamics for biological knowledge generation
7. Enhanced MALDI HiPLEX-IHC workflow for spatial tissue proteomics
8. New MetaboScape^™ release for 4D-Lipidomics^™ and 4D-Metabolomics^™

BUSAN, South Korea–(BUSINESS WIRE)–
At the 22nd Human Proteome Organization World Congress 2023, Bruker Corporation (Nasdaq: BRKR) today announced advances in instrumental methods, consumables and software for 4D-Proteomics, MALDI HiPLEX-IHC spatial tissue proteomics, 4D-Lipidomics and 4D-Metabolomics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918138030/en/

A. Novel scalable AI-powered TIMSquant^™ for label-free quantification

Bruker introduces TIMSquant a scalable, CCS-enabled AI-powered label-free quantification algorithm integrated into Bruker ProteoScape^™. TIMSquant performs accurate quantification of peptides and proteins present in 100s or 1000s samples by using global retention time and collision cross-section (CCS) prediction models. Accurate, large-scale CCS data further increases specificity and quantification consistency based on previously identified peptides and aligned missing values.

Bruker ProteoScape is Bruker’s comprehensive GPU-powered, TIMS DIA-NN-based proteomics software optimized for CCS-centric informatics, and it now comes with the BPS Novor module for de novo peptide sequencing for immunopeptidomics. BPS Novor was co-developed with Rapid Novor Inc., a Canadian software and CRO company. TIMS DIA-NN is a customized version of highly regarded DIA-NN software by Demichev and collaborators.

Dr. Kosuke Ogata, Assistant Professor at Kyoto University, commented: “Ultra-high speed LC-MS from large-scale clinical cohorts harnessing the high duty-cycle of timsTOF technology is a focus of our laboratory. Analysis of non-proteotypic peptides is critical to our research. We have installed the BPS Novorde novo software on Bruker ProteoScape (formerly PaSER) and we are impressed with the real-time speed and high-quality de novo sequences produced.”

Dr. Hanno Steen, Associate Professor at Harvard Medical School & Director of Proteomics at Boston Children’s Hospital, stated: “We focus on the discovery and validation of biomarkers from body fluids, such as plasma, serum, CSF, saliva and urine in high throughput. We leverage the robustness of our timsTOF instruments and real-time Bruker ProteoScape to build large spectral libraries and analyze 1000s of clinical research samples. We have recently expanded our bioinformatics pipeline to run on ProteoScape, and are truly excited by the realistic potential to apply this for the analysis of 10,000s of LC/MS runs in real time to decipher the pathology of pediatric, immunologic, and neurological diseases.”

B. Novel dia-PASEF scan modes

Bruker offers selected upgrades to timsControl acquisition software with the key advances of 300 Hz PASEF and VistaScan^™ technology as downloads from the Bruker web page (Reference 3). The 300Hz dda-PASEF acquisition now allows up to 18,000 CCS-enabled MS/MS spectra per minute with very short LC gradients. VistaScan allows scanning the quadrupole synchronously with the TIMS ramp during the mobility scan to optimally cover the ion population in the ion-mobility-mass to charge plane. (References 1 & 2).

VistaScan enables midia-PASEF, exclusively licensed from Johannes Gutenberg University Mainz. Bruker is initiating a limited early-access program for midia-PASEF for immunopeptidomics and post-translational modifications (PTMs) on the ultra-sensitive timsTOF Ultra. These applications benefit from the sensitivity-with-speed of midia-PASEF, as well as the DDA-like precursor traceability that can be extracted from midia-PASEF data.

C. PreOmics ENRICH Kit for affordable, high-throughput ~3,500 PG plasma proteomics

Bruker, together with PreOmics and Biognosys are now offering further improved high-throughput, affordable, medium-depth plasma proteomics kits and CRO services for reliably quantifying ~3,500 protein groups using PreOmics ENRICH-iST microbeads (SP3 technology) from minimal sample amounts and various species without antibodies/aptamers.

D. PepSep^™ ULTRA XL and PepSep^™ MAX HT columns

Bruker announced the launch of the PepSep^™ ULTRA XL and PepSep^™ MAX HT columns. The PepSep ULTRA XL was designed for long LC gradients, e.g. for DDA-PASEF spectral library generation, which can improve confidence and coverage in peptide and protein identification during short gradients in DIA-PASEF analysis. The PepSep MAX HT is optimized for short-gradients (<15 min run0times) used for high throughput proteomics.

Dr. Byoung-Kyu Cho, Assistant Professor at Washington University School of Medicine and Proteomics Lead at Mass Spectrometry Technology Access Center (MTAC) commented: “PepSep MAX HT columns have brought a remarkable transformation to our mass spectrometry endeavors. This compact column stands out with superior throughput, enduring robustness, and an interface that is user-friendly, making it easy to operate. To all colleagues in search of top-tier high-throughput data, I endorse the PepSep MAX HT.”

E. TwinScape digital twin functionality in Bruker ProteoScape software

To ensure optimal run conditions for every sample, Bruker introduces TwinScape^™, a digital twin for the timsTOF platform, using Bruker ProteoScape software and the Biognosys iRT kit. TwinScape continuously monitors key parameters to ensure that complex assays and large studies are run under optimal conditions, supporting real-time QC with the iRT kit, which contains eleven non-naturally occurring synthetic peptides. The iRT kit peptides have been optimized for stability, sensitivity, rt spacing and peptide CCS.

Dr. Roman Fischer, Associate Professor at University of Oxford, commented: “At the Centre for Translational Proteomics (CTP), we provide services for clients interested in deep proteomes from small sample amounts. Clinical proteomics and spatial proteomics both of require characterization of large sample cohorts at high throughput. Bruker ProteoScape monitors the sample and data quality in real-time, exploiting the outstanding robustness of the timsTOF platforms for high-throughput deep proteomics.”

F. Biological knowledge generation from 4D-Proteomics with Mass Dynamics

Bruker’s collaboration with Prof. Andrew Webb at WEHI, co-founder of Mass Dynamics Pty Ltd, has led to the integration of data from Bruker ProteoScape^™ and now Spectronaut^® with Mass Dynamics interactive visualization tools for knowledge extraction to allow scientists to answer more biological questions.

G. Novel SpatialOMx workflows enhancing 4D-Proteomics

In collaboration with AmberGen, Bruker further advances the novel MALDI HiPLEX-IHC workflow for spatial proteomics based on antibody-based localization of target proteins with a significantly enhanced probe selection and robust workflows similar to IHC protocols, adapting HiPLEX-IHC to a variety of areas from immunooncology to neuropathology.

Dr. Bernd Bodenmiller, Professor University of Zuerich and ETH Zuerich, and Director of the Department of Quantitative Biomedicine, noted: “Recent research shows that spatial proteomics provides biological context about tissue neighborhoods by providing spatially defined biomarkers. The cellular arrangements and location of proteins in the tissue microenvironment elucidates biological mechanisms in disease or homeostasis, supporting novel precision medicine applications. Using HiPLEX-IHC tissue imaging on our timsTOF fleX enhances our multiomic spatial view of tissue ecosystems.”

H. Novel MetaboScape software for 4D multiomic research

In the new release of MetaboScape^®, CCS-enabled 4D-Lipidomics is complemented by integrating semi-quantitative analysis utilizing stable isotopically labeled lipid standards.

Dr. Heiko Hayen, Institute of Inorganic and Analytical Chemistry, University of Münster, Germany, said: “The new CCS-enabled workflow with T-ReX 4D in MetaboScape allows us to accurately normalize our lipid class concentrations with labelled internal standards. By adopting this solution, we observed a noticeable improvement in standard deviations among covered lipids, enhancing reproducibility in our lipidomics research.”

Dr. Viswa Colluru, CEO and Founder of Enveda Biosciences, said: “The open software ecosystem provided by Bruker is at the foundation of our discovery platform. Their CCS-enabled workflows give us an edge in discerning compounds from nature with better resolution. Bruker’s commitment to innovation and customer support makes them a great partner and helps achieve our mission of translating nature into medicine.”

References:

1. Distler et al., bioRxiv 2023.01.30.526204, https://doi.org/10.1101/2023.01.30.526204
2. Skowronek et al., Molecular & Cellular Proteomics, Feb 2023; 22(2):100489-100489, https://doi.org/10.1016/j.mcpro.2022.100489
3. https://www.bruker.com/protected/de/services/software-downloads/mass-spectrometry/acquisition-software.html

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visit www.bruker.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918138030/en/

Media

Petra Scheffer

Bruker Daltonics Marketing Communications

T: +49 (421) 2205-2843

E: [email protected]

Investor Relations

Justin Ward

Sr. Director Investor Relations & Corp Development

T: +1 (978) 663–3660, ext. 1479

E: [email protected]

KEYWORDS: Asia Pacific South Korea

INDUSTRY KEYWORDS: Research Technology Medical Supplies Health Technology Software Biotechnology General Health Pharmaceutical Health Science

MEDIA:

Logo

Photo

Fig. 1: TIMSquant for CCS-aware, AI-powered quantification (Graphic: Business Wire)

Photo

(Graphic: Business Wire)

Coeur Announces Initial Production From Rochester Expansion and Substantial Completion of Construction

CHICAGO–(BUSINESS WIRE)–
Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today announced the achievement of several critical milestones at its major Rochester expansion project in Nevada, including the production of the first silver and gold ounces. Following a ramp-up period expected to last into early 2024, Rochester is expected to drive a step-change in the Company’s overall production levels, cost profile, and cash flow.

Recent Project Milestone Highlights:

• First Silver and Gold Produced – Metal production from the new Stage VI leach pad and Merill-Crowe process plant leach began mid-month with initial doré expected to be poured today. Approximately one-third of the eight million tons of ore on the new pad are currently under leach. The Merrill-Crowe plant is achieving a flow rate of roughly 3,500 gallons per minute (“gpm”) of solution. Full ramp-up to commercial production of around 13,000 gpm is expected to be achieved in early 2024.
• Construction of Crushing Circuit Substantially Complete – With the primary gyratory crusher now installed, construction of the new three-stage crushing circuit is now substantially complete. Once fully ramped-up, throughput is expected to average 32 million tons per year, which is approximately 2.5x higher than historical levels, making Rochester one of the world’s largest open pit heap leach operations
• Mining Test Achieves Design Capacity – A multi-day test of truck and loading capacity was completed earlier this month to ensure that the mine can support the higher throughput rates associated with the newly-configured Rochester circuit. This test confirmed the mine’s ability to safely support the designed capacity of up to 100,000 tons per day in 2023 and up to 132,000 tons per day in 2024. Data gathered during the test will be used to refine processes and identify opportunities for additional efficiencies in cycle and load counts.

“The achievement of these three critical milestones marks the beginning of a new growth phase for Coeur,” said Mitchell J. Krebs, President and Chief Executive Officer. “The focus is now shifting to commissioning, ramp-up, and mine optimization initiatives as well as prioritizing several adjacent exploration targets located on Rochester’s prospective 69-square mile land package. Coeur’s project team has overcome numerous challenges over the last three years to arrive at this key inflection point and deserves thanks for their resilience and commitment.”

About Coeur

Coeur Mining, Inc. is a U.S.-based, well-diversified, growing precious metals producer with four wholly-owned operations: the Palmarejo gold-silver complex in Mexico, the Rochester silver-gold mine in Nevada, the Kensington gold mine in Alaska and the Wharf gold mine in South Dakota. In addition, the Company wholly-owns the Silvertip silver-zinc-lead exploration project in British Columbia.

Cautionary Statements

This news release contains forward-looking statements within the meaning of securities legislation in the United States and Canada, including statements regarding expected timelines for completion of the Rochester expansion project and expected performance and benefits of the Rochester expansion project including impacts on production, costs and cash flow. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Coeur’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include, among others, the risk that expected project timelines are not met or project benefits not realized, the risks and hazards inherent in the mining business (including risks inherent in developing large-scale mining projects, environmental hazards, industrial accidents, weather or geologically-related conditions), changes in the market prices of gold and silver and a sustained lower price or higher treatment and refining charge environment, the uncertainties inherent in Coeur’s production, exploratory and developmental activities, including risks relating to permitting and regulatory delays, changes in mining laws, ground conditions and, grade and recovery variability, any future labor disputes or work stoppages (involving the Company and its subsidiaries or third parties), the uncertainties inherent in the estimation of mineral reserves, changes that could result from Coeur’s future acquisition of new mining properties or businesses, the loss of access or insolvency of any third-party refiner or smelter to which Coeur markets its production, the potential effects of the COVID-19 pandemic, including impacts to the availability of our workforce, continued access to financing sources, government orders that may require temporary suspension of operations at one or more of our sites and effects on our suppliers or the refiners and smelters to whom the Company markets its production and on the communities where we operate, the effects of environmental and other governmental regulations and government shut-downs, the risks inherent in the ownership or operation of or investment in mining properties or businesses in foreign countries, Coeur’s ability to raise additional financing necessary to conduct its business, make payments or refinance its debt, as well as other uncertainties and risk factors set out in filings made from time to time with the United States Securities and Exchange Commission, and the Canadian securities regulators, including, without limitation, Coeur’s most recent report on Form 10-K and Form 10-Q. Actual results, developments and timetables could vary significantly from the estimates presented. Readers are cautioned not to put undue reliance on forward-looking statements. Coeur disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or otherwise. Additionally, Coeur undertakes no obligation to comment on analyses, expectations or statements made by third parties in respect of Coeur, its financial or operating results or its securities. This does not constitute an offer of any securities for sale.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918053073/en/

Coeur Mining, Inc.

Jeff Wilhoit, Director, Investor Relations

Phone: (312) 489-5800

www.coeur.com

KEYWORDS: Illinois Alaska Idaho South Dakota Nevada Colorado Australia/Oceania United States Canada New Zealand North America Australia

INDUSTRY KEYWORDS: Machine Tools, Metalworking & Metallurgy Natural Resources Manufacturing Mining/Minerals

MEDIA:

Logo

Three Amwell® Health System Clients to Lead Hybrid Care Panel at Oracle Health Conference

Leaders from Aultman Health, Banner Health and Children’s National Hospital to share successes with Amwell platforms and Oracle Health integration

BOSTON–(BUSINESS WIRE)–Amwell® (NYSE: AMWL), a leader in digital healthcare enablement, today announced three of its partner health systems will lead a panel discussion during the 2023 Oracle Health Conference.

Representatives from renowned health systems Aultman Health, Banner Health and Children’s National Hospital will co-present “Interweaving In-Person, Virtual and Digital Care Delivery into Your EHR” from 12:30 p.m. to 1:15 p.m. PDT Tuesday, Sept. 19. The panelists will discuss how their organizations use Amwell hybrid care solutions, their Oracle Health EHR ecosystems, and existing clinical, financial and patient workflows to improve outcomes.

Speakers include:

• Pete Kandis, vice president of operations, Aultman Health
• Belinda Brummett,senior director of digital health engagement, Banner Health
• Jessica Herstek, M.D., chief medical informatics officer, Children’s National Hospital

Attendees will hear from panelists about the different uses of the Amwell Converge™ platform to enable hybrid care, and the outcomes they are seeing from virtual and digital programs. Listeners will also gain insight into the digital behavioral health platform SilverCloud® by Amwell, which is used to manage mental healthcare between in-person visits. The panel will also share how Amwell solutions and the Oracle Health EHR integrate to improve provider and patient experiences, support nurses providing in-person care in school settings across the Washington, D.C. metro area, and help address behavioral health needs and improve rates of depression and anxiety in the Phoenix area.

“These organizations are at the forefront of embracing the evolution toward hybrid care, blazing the path and demonstrating tangible value to the industry. While they serve diverse patient populations across different parts of the country, they’ve all proven firsthand how the blend of in-person, virtual and automated care can benefit providers, patients and the healthcare system as a whole. Amwell is proud to have enabled their incredible impact,” said Roy Schoenberg, president and chief executive officer of Amwell.

Oracle Health Conference attendees can register for the in-person session here.

About Amwell

Amwell provides a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, insurers, patients and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. The company offers a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the hybrid care of more than 55 health plans, which collectively represent more than 90 million covered lives, and many of the nation’s largest health systems, representing over 2,000 hospitals, have access to Amwell solutions. For more information, please visit https://business.amwell.com/.

©2023 American Well Corporation. All rights reserved. Amwell®, SilverCloud®, Conversa®, Converge^TM, Carepoint^TM and the Amwell Logo are registered trademarks or trademarks of American Well Corporation.

Trademarks

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company–ushering in the new era of cloud computing.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918932682/en/

Media Contact:

Amwell

Angela Vogen

Head of External Communications

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Data Management Mental Health Health Technology Hospitals Health Technology Software

MEDIA:

Logo

Black Rifle Coffee Appoints Danya Kennedy as Chief Revenue Officer

SALT LAKE CITY–(BUSINESS WIRE)–
Black Rifle Coffee (NYSE: BRCC) (“BRCC” or the “Company”), a rapidly growing and mission-driven coffee company founded to support veterans, active-duty military, and first responders and serve a broad customer base by connecting consumers with great coffee and a unique brand experience, today announced the appointment of Danya Kennedy as Chief Revenue Officer. In her role, Danya will support the Company’s efforts to further build on its strong brand momentum and drive profitable, sustainable growth across channels.

Danya brings more than two decades of experience as a sales and growth leader, driving results with Food, Drug, Mass (FDM) and Omni retail partners. In her most recent role, she served as President of Ethique Consumer Products’ North America business, a New Zealand-based concentrated beauty products company experiencing double digit direct to consumer growth. While there, she led the North American Go-to-Market Strategy, including its entry into the U.S. FDM market, while also enhancing digital transformation. Prior to her time at Ethique, Danya held roles of increasing responsibility for six years at Mars Petcare including VP of Customer Development and Managing Director of Sales Planning, Category Insights & Solutions. While serving as VP of Customer Development, Danya helped drive step-change growth in retail partners such as Amazon, Chewy, Target, Albertson’s, and Kroger. Before that, Danya spent nearly 10 years at Reckitt Benckiser leading businesses in North America and Europe. Danya’s appointment was effective September 5^th.

“Danya brings an immense amount of experience to BRCC, and I am excited to welcome her to our executive team,” said Evan Hafer, Founder and Co-CEO of Black Rifle Coffee. “As we continue to strengthen our management team, Danya’s experience will be incredibly beneficial as we look to expand to new markets and continue to build towards sustainable, profitable growth over the long term.”

About Black Rifle Coffee Company

Black Rifle Coffee Company (BRCC) is a Veteran-founded coffee company serving premium coffee to people who love America. Founded in 2014 by Green Beret Evan Hafer, Black Rifle develops their explosive roast profiles with the same mission focus they learned while serving in the military. BRCC is committed to supporting Veterans, active-duty military, first responders and the American way of life. To learn more about BRCC, visit www.blackriflecoffee.com, follow BRCC on social media, or subscribe to Coffee or Die Magazine’s daily newsletter at https://coffeeordie.com/presscheck-signup.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230915854271/en/

Investors

Tanner Doss: [email protected]


Media

PR for BRCC: [email protected]

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Retail Defense Convenience Store Supermarket Veterans Food/Beverage

MEDIA:

Posted on September 18, 2023 7:03 am

Joby Selects Dayton, Ohio, Birthplace of Aviation, For First Scaled Manufacturing Facility

Joby Selects Dayton, Ohio, Birthplace of Aviation, For First Scaled Manufacturing Facility

• Joby plans to build facility capable of delivering up to 500 aircraft per year

• 140-acre site at Dayton International Airport has potential to support significant further growth, with space to build up to two million square feet of manufacturing facilities

• Joby plans to invest up to $500 million, creating up to 2,000 jobs

• Up to $325 million in state and local incentives available to support scaling

• U.S. Department of Energy has invited Joby to submit a Part II application for a Title XVII loan to support the development of the facility, as a clean energy project

• Joby plans to use existing nearby buildings to begin near term operations

SANTA CRUZ, Calif. & DAYTON, Ohio–(BUSINESS WIRE)–
Joby Aviation, Inc. (NYSE:JOBY), a company developing electric vertical take-off and landing (eVTOL) aircraft for commercial passenger service, today announced it plans to locate its first scaled aircraft production facility in Dayton, Ohio, the birthplace of aviation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918669349/en/

A render of Joby’s proposed manufacturing facility in Dayton, Ohio, which will support production of up to 500 electric vertical take-off and landing (eVTOL) aircraft per year. (Photo Credit: Joby Aviation)

The Wright Brothers, who invented and flew the first powered aircraft, lived and worked in Dayton and opened the first airplane factory in the United States there in 1910. The city is also home to Wright-Patterson Air Force Base, and the headquarters of the U.S. Air Force Research Laboratories which has played a key role in supporting Joby’s development.

Joby plans to build a facility capable of delivering up to 500 aircraft per year at the Dayton International Airport, supporting up to 2,000 jobs. The 140-acre site it has selected has the potential to support significant further growth over time, providing enough land to build up to two million square feet of manufacturing space. Construction of the scaled Ohio facility is expected to start in 2024 and it is expected to come online in 2025. Joby plans to use existing nearby buildings to begin near-term operations.

The State of Ohio, JobsOhio and local political subdivisions have offered incentives and benefits of up to $325 million to support the development of the facility, while Joby plans to invest up to $500 million as it scales operations at the site. Joby is also announcing today that it has been invited by the U.S. Department of Energy to submit a Part II Application for financing under the Title XVII Loan Guarantee Program, which provides access to low-interest loans for clean energy projects and would support the scaling of the facility.

Joby’s long-term investor, Toyota, who worked with Joby on the design and successful launch of the company’s Pilot Production Line in Marina, California, plans to continue to advise Joby as it prepares for scaled production of its commercial passenger air taxi in Ohio.

“We’re building the future of aviation right where it all started, in Dayton, Ohio,” said JoeBen Bevirt, Founder and CEO of Joby. “The Wright Brothers harnessed revolutionary technology of their time to open up the skies, and we intend to do the same — this time, bringing quiet and emissions-free flight that we hope will have an equally profound impact on our world.

“The U.S. continues to lead the way on introducing this technology, with unprecedented levels of support across all areas and levels of government. We’re incredibly grateful to Governor Mike DeWine, Lt. Governor Jon Husted, Senator Sherrod Brown, Senator JD Vance, Representative Mike Turner, and the team at JobsOhio for their support, as well as the representatives of the many other states we worked with during this process.

“Our partnership with Ohio is a great example of how successful public-private partnership amongst industry, local, state and federal government can bring important new technology to life.”

Joby plans to start hiring in the coming months, with early roles expected to focus on the build out of the scaled facility and the machining of parts that will initially be incorporated into Joby’s California low-volume production line. Those interested in applying for roles at Joby’s Ohio facility can register their interest at www.jobyinohio.com.

Joby’s production aircraft is designed to transport a pilot and four passengers at speeds of up to 200 mph, with a maximum range of 100 miles and a revolutionary quiet noise profile that is barely audible against the backdrop of cities. The company plans to operate these aircraft as part of aerial ridesharing networks in cities and communities around the world, starting in 2025, building on partnerships it has developed with Delta and Uber.

An event to celebrate the announcement will be held later today at Hawthorn Hill, the home of Orville Wright. The event is expected to conclude with a ceremonial flypast of a replica Model “B” Flyer, the world’s first production airplane.

Joby’s selection of Ohio as the site for its first scaled aircraft production facility followed an extensive competitive site selection process and is contingent upon standard due diligence, state and local approvals of incentives, permitting and other legal and regulatory matters as customarily accompany such investment projects.

Joby’s headquarters, research and development, and pilot production facility will remain in California. With approximately 150 open positions across the Company’s three Northern California sites, Joby continues to grow its presence in the state.

Media assets, including renders of the proposed facility and footage of Joby’s aircraft in flight, are available here.

The celebratory event can be watched live at 10:00am ET today via www.jobsohio.com/live.

Joby is grateful for the support expressed by many in the Dayton area and across the state of Ohio. Comments regarding Joby’s decision to locate its manufacturing facility in Ohio are included below:

Governor Mike DeWine:

“Ohio’s legacy in aviation begins with the Wright Brothers and continues with Joby Aviation as they launch a new era in aviation manufacturing and aerial mobility in Dayton. The aircraft that will roll off Joby Ohio’s production lines will redefine urban transportation and contribute to a fundamental change in the way people and goods travel. We welcome Joby and celebrate the new chapter of air mobility history that will be made in Ohio, the Heart of Aviation.”

Lt. Governor Jon Husted:

“Today’s announcement didn’t come about by chance, it was earned through 20 years of strategic planning in the Dayton region, leading us to be in the best possible position for a company like Joby to expand their operations from California to Ohio. Dayton has solidified itself as the center of aviation innovation, from the Wright Brothers to Wright-Patterson AFB, but for over 100 years, that innovation has not been successfully translated into the manufacturing of aircraft and the thousands of jobs that come with it. Today, that elusive aspiration becomes reality.”

Senator Sherrod Brown:

“From the Wright brothers to John Glenn to Ohio aerospace workers across the state today – the story of modern aviation is being written in Ohio. Joby Aviation understands Ohio’s proud history of leadership in aerospace innovation and that is why I fought to ensure that they invested here. Our state continues to lead the country in aerospace innovation. The technologies of the future, like the flying cars from Joby Aviation, will be invented in Ohio and manufactured in Ohio.”

Senator JD Vance:

“Ohio is the undisputed home of aviation. I’m excited that new, innovative flight technologies have found a home in the Dayton area, just miles away from where the Wright brothers started it all. We want to see Ohio become the research, development, and manufacturing hub for the future of military and civilian aerospace technologies. Joby Aviation’s new investment is a welcome step toward advancing that goal. I look forward to working with them and wish them the best of luck.”

Representative Mike Turner:

“Joby Aviation is a leader in aviation innovation and a pioneer in the air taxi market. Today’s announcement that Joby has chosen the Miami Valley for the site of its new manufacturing facility further signals to other companies in the aviation and innovation space that the spirit of the Wright Brothers in this region is alive and thriving. I look forward to further working with Joby to grow the future of advanced air mobility here in Dayton, the birthplace of aviation.”

Dayton Development Coalition President and CEO Jeff Hoagland:

“When Lt. Governor Husted spoke at the DDC’s Annual Meeting in February 2022 and challenged us to land an eVTOL manufacturing facility in the Dayton Region, we were ready. Twenty years ago, we developed a strategy aimed at supporting an emerging industry that not only aligned with the missions at Wright-Patt, but represented the opportunity for private industry investment, as well. Our region’s eVTOL tagline has urged companies to leverage the region’s network of resources and, ‘Come here to test, stay here to build.’ Joby is doing exactly that.”

JobsOhio President and CEO, J. P. Nauseef:

“When fully executed, the agreement and the forward vision Joby has shared today will mark the largest aviation job creation deal in Ohio history. Today, we continue Ohio’s historic legacy as the past – the present – and the future of aviation innovation and further affirm we are in the midst of an economic renaissance of the American Midwest – with Ohio leading the way.”

Brig. Gen. Scott Cain, Department of the Air Force Technology Executive Officer and Air Force Research Laboratory (AFRL) Commander:

“Through AFWERX’s Agility Prime program we have worked with several companies to accelerate the development and adoption of advanced aerial mobility technologies, such as electric vertical take-off and landing (eVTOL) aircraft, and we’re thrilled to see the results of that investment strengthening the Defense Industrial Base.”

Gail Grimmett, Senior Vice President – Sustainability Performance & Strategic Partnerships – Delta Air Lines:

“This is a milestone to celebrate. Joby is one step closer to making eVTOL for commercial use a reality, and at the birthplace of aviation no less. We are excited about our partnership with Joby and how the new manufacturing site will play a critical role in helping Delta deliver a continued elevated and sustainable experience for our customers.”

Brandi Davis-Handy, Chief Customer Officer – AES US Utilities:

“AES Ohio has a long history of supporting the needs of our residential and commercial customers. Joby Aviation’s announcement further positions the Dayton Region to play a significant role in the energy transition and the electrification of the aviation industry.”

About Joby

Joby Aviation, Inc. (NYSE:JOBY) is a California-based transportation company developing an all-electric, vertical take-off and landing air taxi which it intends to operate as part of a fast, quiet, and convenient service in cities around the world. To learn more, visit www.jobyaviation.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the development and performance of our aircraft; the growth of our manufacturing capabilities, including the size, capacity, potential production volumes, planned investments, staffing levels, available incentives and timing of our planned scaled manufacturing facility in Dayton, Ohio and our ongoing plans for our facilities in California; our regulatory outlook, progress and timing, including our expectation to start commercial passenger service in 2025, the expected timing of type certification and our plan to begin initial service operations with the Department of Defense in 2024; our plans to submit a Part II application for a Title XVII loan; our business plan, objectives, goals and market opportunity; plans for, and potential benefits of, our strategic partnerships; and our current expectations relating to our business, financial condition, results of operations, prospects, capital needs and growth of our operations. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. All forward looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including: our ability to launch our aerial ridesharing service and the growth of the urban air mobility market generally; our ability to produce aircraft that meet our performance expectations in the volumes and on the timelines that we project, and our ability to launch our service; the competitive environment in which we operate; our future capital needs; the completion of standard due diligence regarding our planned manufacturing site in Dayton, Ohio; formal approval of state and local incentives, permitting and other legal and regulatory matters as customarily accompany such investment projects; approval of any Title XVII loan application that we may make, which is not guaranteed, is solely dependent on the results of the U.S. Department of Energy’s review and may not align with the terms we propose; our ability to adequately protect and enforce our intellectual property rights; our ability to effectively respond to evolving regulations and standards relating to our aircraft; our reliance on third-party suppliers and service partners; uncertainties related to our estimates of the size of the market for our service and future revenue opportunities; and other important factors discussed in the section titled “Risk Factors” in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2023, and in future filings and other reports we file with or furnish to the SEC. Any such forward-looking statements represent management’s estimates and beliefs as of the date of this presentation. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918669349/en/

Joby Aviation

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: United States North America California Ohio

INDUSTRY KEYWORDS: Air Transport Public Policy/Government Aerospace Manufacturing White House/Federal Government Transportation State/Local Travel

MEDIA:

Logo

Photo

A render of Joby’s proposed manufacturing facility in Dayton, Ohio, which will support production of up to 500 electric vertical take-off and landing (eVTOL) aircraft per year. (Photo Credit: Joby Aviation)

Origin Materials Awarded BioMADE Funding to Advance Department of Defense Sustainability Goals

World’s leading carbon-negative materials company to develop samples of bio-based carbon black and polymers for Department of Defense fleet decarbonization

WEST SACRAMENTO, Calif.–(BUSINESS WIRE)–Origin Materials, Inc. (“Origin,” “Origin Materials,” or “The Company”) (Nasdaq: ORGN, ORGNW), the world’s leading carbon negative materials company with a mission to enable the world’s transition to sustainable materials, announced today that it has been awarded funding from BioMADE, a Manufacturing Innovation Institute catalyzed by the U.S. Department of Defense.

BioMADE announced a suite of projects last week that aim to aid in the advancement of Department of Defense supply chain resiliency and sustainability goals, re-shore manufacturing jobs to the United States, and enhance the domestic bioindustrial manufacturing ecosystem. Origin Materials is one of nine projects announced by BioMADE, totaling $18.7 million in funding.

As part of its project, Origin will leverage its technology platform to develop samples of bio-based polymers and bio-based carbon black, which can be used to make more sustainable tires and other products, which could support Department of Defense fleet decarbonization efforts.

“This grant reflects the strong momentum for Origin’s technology platform to help solve the greatest sustainability challenges of our time,” said Origin Materials Co-CEO Rich Riley. “We are excited that Origin has been selected to pursue this far-reaching initiative for American manufacturing.”

“These projects will help unlock the benefits of bioindustrial manufacturing for all Americans – from everyday consumers to farmers to warfighters,” said Dr. Douglas Friedman, Chief Executive Officer at BioMADE in a statement. “By creating new products and transforming how we domestically manufacture existing products, these projects – and the bioindustrial manufacturing industry at large – have the potential to positively impact nearly every aspect of our lives.”

“These projects represent the breadth and depth of what can be accomplished with bioindustrial manufacturing,” said Dr. Melanie Tomczak, Head of Programs and Chief Technology Officer at BioMADE in a statement. “These innovations can play a key role in enhancing our military readiness, strengthening domestic supply chains, supporting American farmers, and creating jobs in rural communities.”

More information on the new suite of projects is available at https://www.biomade.org/news/new-projects-2023.

About Origin Materials

Headquartered in West Sacramento, Origin Materials is the world’s leading carbon negative materials company. Origin’s mission is to enable the world’s transition to sustainable materials. For over a decade, Origin has developed a platform for turning the carbon found in inexpensive, plentiful, non-food biomass such as sustainable wood residues into useful materials while capturing carbon in the process. Origin’s patented technology platform can help revolutionize the production of a wide range of end products, including clothing, textiles, plastics, packaging, car parts, tires, carpeting, toys, fuels, and more with a ~$1 trillion addressable market. In addition, Origin’s technology platform is expected to provide stable pricing largely decoupled from the petroleum supply chain, which is exposed to more volatility than supply chains based on sustainable wood residues. Origin’s patented drop-in core technology, economics and carbon impact are supported by a growing list of major global customers and investors.

For more information, visit www.originmaterials.com.

Cautionary Note on Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Origin Materials’ business strategy, estimated total addressable market, ability to enter new end-markets, ability to develop new product categories, ability of products to support the Department of Defense’s fleet decarbonization efforts, commercial and operating plans, and product development plans. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Origin Materials and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Origin Materials. These forward-looking statements are subject to a number of risks and uncertainties, including that Origin Materials may be unable to successfully commercialize its products; the effects of competition on Origin Materials’ business; the uncertainty of the projected financial information with respect to Origin; disruptions and other impacts to Origin’s business as a result of outbreaks such as the COVID-19 pandemic, Russia’s military intervention in Ukraine, the impact of severe weather events, and other global health or economic crises; changes in customer demand; and those factors discussed in the Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on August 9, 2023, under the heading “Risk Factors,” and other documents Origin Materials has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Origin Materials presently does not know, or that Origin Materials currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Origin Materials’ expectations, plans, or forecasts of future events and views as of the date of this press release. Origin Materials anticipates that subsequent events and developments will cause its assessments to change. However, while Origin Materials may elect to update these forward-looking statements at some point in the future, Origin Materials specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Origin Materials’ assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918300159/en/

Investors:

[email protected]

Media:

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Green Technology Government Technology Manufacturing Defense Environment Automotive Other Defense Sustainability Other Natural Resources Alternative Energy Natural Resources Energy Other Manufacturing Textiles General Automotive Packaging Engineering Chemicals/Plastics

MEDIA:

Logo

Gannett Announces Additional Debt Reduction

MCLEAN, Va.–(BUSINESS WIRE)–
Gannett Co., Inc. (“Gannett”, “we”, “us”, “our”, or the “Company”) (NYSE: GCI) announced today it has repurchased approximately $15.0 million of 6.00% first lien notes due November 1, 2026 (the “2026 Senior Notes”) for approximately $13.1 million, representing a discount to par value. In connection with the repurchase of the 2026 Senior Notes, the Company received a waiver from certain lenders under its five-year senior secured term loan facility that reduced the scheduled amortization payment for the fiscal quarter ending September 30, 2023 payable to those lenders by the amount spent by the Company to repurchase the 2026 Senior Notes.

“We continue to have a great relationship with Apollo and work with them on ways to increase value for our shareholders. Based on the agreement, Apollo waived $13.1 million of our scheduled amortization payment for the fiscal quarter ending September 30, 2023 to repurchase $15.0 million of our 2026 Senior Notes, representing a discount to par value of 87.5%,” said Michael Reed, Chairman and Chief Executive Officer. “Year to date, we have repaid approximately $115 million of debt, and we believe we remain on track to repay more than $130 million of debt and reduce our first lien net leverage below 2.0x by the end of 2023. We will continue to prioritize debt repayment, and we believe the strategic actions we are implementing to optimize our capital structure will enable us to accelerate the creation of additional value for our shareholders. We appreciate the support and flexibility of Apollo, and we look forward to providing additional updates.”

About Gannett

Gannett Co., Inc. (NYSE: GCI) is a subscription-led and digitally-focused media and marketing solutions company committed to empowering communities to thrive. With an unmatched reach at the national and local level, Gannett touches the lives of millions with our Pulitzer Prize-winning content, consumer experiences and benefits, and advertiser products and services. Our current portfolio of media assets includes the USA TODAY NETWORK, which includes USA TODAY, and local media organizations in 43 states in the United States, and Newsquest, a wholly-owned subsidiary operating in the United Kingdom. We also own digital marketing services companies under the brand LocaliQ, which provide a cloud-based platform of products to enable small and medium-sized businesses to accomplish their marketing goals. In addition, our portfolio includes what we believe is the largest media-owned events business in the U.S., USA TODAY NETWORK Ventures. To connect with us, visit www.gannett.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain items in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding our business outlook, our ability to create long-term stockholder value, our expectations, in terms of both amount and timing, with respect to debt repayment, our capital structure, our strategy, and our ability to achieve our operating priorities. The Company makes no guarantees or assurances that sales of any of the real estate or other asset sales in negotiation will close. Words such as “expect(s)”, “continue(s),” “believe(s)”, “look forward”, “will”, “remain(s),” and similar expressions are intended to identify such forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties. These and other risks and uncertainties could cause actual results to differ materially from those described in the forward-looking statements, many of which are beyond our control. The Company can give no assurance its expectations will be attained. Accordingly, you should not place undue reliance on any forward-looking statements contained in this press release. For a discussion of some of the risks and important factors that could cause actual results to differ from such forward-looking statements, see the risks and other factors detailed from time to time in the Company’s most recent Annual Report on Form 10-K, our quarterly reports on Form 10-Q, and our other filings with the Securities and Exchange Commission. Furthermore, new risks and uncertainties emerge from time to time, and it is not possible for the Company to predict or assess the impact of every factor that may cause its actual results to differ from those contained in any forward-looking statements. Such forward-looking statements speak only as of the date of this press release. Except to the extent required by law, the Company expressly disclaims any obligation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or change in events, conditions or circumstances on which any statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918615320/en/

For investor inquiries, contact:

Matt Esposito

Investor Relations

703-854-3000

[email protected]

For media inquiries, contact:

Lark-Marie Anton

Corporate Communications

646-906-4087

[email protected]

KEYWORDS: United States North America Virginia

INDUSTRY KEYWORDS: Media Communications Publishing

MEDIA:

Logo

908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

MAVERICK is a Raman-based PAT solution that requires no complex modeling

BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the launch of MAVERICK, an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

MAVERICK offers all the advantages of Raman spectroscopy without the cost and complexities associated with conventional spectroscopic methods. MAVERICK’s purpose-built de novo models automatically process Raman spectra from a wide variety of culture media types and cell lines, delivering actionable process parameters or direct process control actions. Open access to the raw process spectral data also enables Artificial Intelligence (AI) / Machine Learning (ML) experts to extend MAVERICK’s capabilities for more advanced predictive control of critical process parameters or quality attributes.

“Traditional Raman-based analyzers require a sharp learning curve for the user which is time-consuming for initial model building and continued model updates,” said Dr. Seongkyu Yoon, Professor in the Department of Chemical Engineering and the Ward Endowed Professor in Biomedical Sciences at the University of Massachusetts-Lowell. “With MAVERICK, all the hurdles of traditional Raman have been overcome. This device provides very good measurements independently of cell line, media, and scale, which is very beneficial.”

The MAVERICK hub can monitor up to six bioreactor modules simultaneously, with independent analog/digital control of feed systems for each. Remote real-time web access to bioreactor status and settings is also supported through the MAVERICK hub. Biopharmaceutical process development scientists and manufacturers will be able to enhance process understanding and implement dynamic control strategies quicker and easier, leading to faster time to market and more robust and efficient processes.

“As the biopharmaceutical industry adopts Process Analytical Technologies to drive the advancement of Biopharma 4.0, scientists need an array of tools that enable them to monitor and control their process in real time,” said Christopher D. Brown, Chief Product Officer and co-founder of 908 Devices. “We are addressing this need with our full complement of devices. With MAVERICK, we are introducing a new platform that offers easy-to-integrate in-line analysis and control without the need for substantial expert configuration or set-up. In addition, as a spectroscopic-based device, MAVERICK is extensible to other analytes and parameters.”

908 Devices experts will share more details about MAVERICK during the following events, including at the BioProcess International (BPI) conference in Boston:

• Webinar (virtual) – September 18 at 11am ET – Chris Brown, CPO and co-founder, and Graziella Piras, Senior Director of Strategic Marketing at 908 Devices, will co-present this webinar about advanced in-line monitoring for bioprocessing, which will introduce the MAVERICK solution to the marketplace.
• Scientific presentation – September 19 at 9:30am ET – Chris Brown will host a session within the Cell Culture Track at BPI Boston titled, “In-line monitoring of bioprocess parameters for the 21^st century,” which will outline advancements in Biopharma 4.0 and the current state of spectroscopy-based approaches.
• Breakfast seminar – September 19 at 10am ET – Nick Randall, Bioprocessing Product Manager at 908 Devices, will conduct a talk at BPI Boston about “out-of-the-box implementation of optical monitoring of critical process parameters,” which will showcase the benefits and use cases of MAVERICK.
• You can also find 908 Devices at BPI Boston at booth #860.

• Scientific presentation – September 28 at 9am CET – During the World Smart Bioprocessing Summit-Pharma 4.0 in Berlin, Steve Driscoll, Senior Scientist at 908 Devices, will speak about the strengths and limitations of in-line multivariate bioprocess analysis. You can also find 908 Devices at Table 6 during the summit.

MAVERICK is part of 908 Devices’ suite of devices to help expedite bioprocessing development, including MAVEN – introduced earlier this year — and REBEL. To learn more about 908 Devices, please visit: 908devices.com.

About 908 Devices

908 Devices is revolutionizing chemical and biochemical analysis with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma/biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic sampling and separations, software automation, and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC’s website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230918740819/en/

Media

Katie Johnston

PAN Communications for 908 Devices

[email protected]

Investor

Carrie Mendivil

[email protected]

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Medical Devices

MEDIA:

Logo